Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.63 |
| ▸ | CA2 | P00918 | 9/20 | 0.63 |
| ▸ | CA12 | O43570 | 6/20 | 0.63 |
| ▸ | CA9 | Q16790 | 6/20 | 0.63 |
| ▸ | AOC2 | O75106 | 4/20 | 0.48 |
| ▸ | MAOB | P27338 | 5/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23852233 | 1.00 | CA1 (0.63) | CA1CA2CA12CA9AOC2 | |
| SCHEMBL23370042 | 0.87 | MAOB (0.64) | CA1CA2CA12CA9AOC2 | |
| SCHEMBL16767547 | 0.87 | CA12 (0.47) | CA1CA2CA12CA9AOC2 | |
| SCHEMBL16767549 | 0.87 | CA12 (0.47) | CA1CA2CA12CA9AOC2 | |
| SCHEMBL24906961 | 0.85 | AOC2 (0.67) | CA1CA2CA12CA9AOC2 | |
| SCHEMBL23329639 | 0.85 | MAOB (0.46) | CA1CA2CA12CA9AOC2 | |
| SCHEMBL21768043 | 0.83 | AOC3 (0.50) | CA1CA2CA12CA9MAOB | |
| SCHEMBL21780054 | 0.83 | AOC3 (0.50) | CA1CA2CA12CA9MAOB | |
| SCHEMBL21889843 | 0.83 | MAOB (0.45) | CA1CA2CA12CA9AOC2 | |
| SCHEMBL23718599 | 0.83 | AOC3 (0.50) | CA1CA2CA12CA9MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220106289-A1 | NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106289-A1 | NLRP3 INHIBITORS | NLRP3, NLRP1, NOD1 | CA1 4076/4885CA2 3351/4885CA12 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.